Evidence
World J Diabetes. 2023 May 15;14(5):549-559. doi: 10.4239/wjd.v14.i5.549.
ABSTRACT
Fatty liver disease is defined as liver condition characterized by hepatic steatosis, closely related to pathological conditions in type 2 diabetes and obesity. The high prevalence of fatty liver disease in obese patients with type 2 diabetes reached 70%, reflecting the importance of these conditions with fatty liver. Although the exact pathological mechanism of fatty liver disease, specifically non-alcoholic fatty liver disease (NAFLD) remains not completely revealed, insulin resistance is suggested as the major mechanism that bridged the development of NAFLD. Indeed, loss of the incretin effect leads to insulin resistance. Since incretin is closely related to insulin resistance and the resistance of insulin associated with the development of fatty liver disease, this pathway suggested a potential me-chanism that explains the association between type 2 diabetes and NAFLD. Furthermore, recent studies indicated that NAFLD is associated with impaired glucagon-like peptide-1, resulting in decreased incretin effect. Nevertheless, improving the incretin effect becomes a reasonable approach to manage fatty liver disease. This review elucidates the involvement of incretin in fatty liver disease and recent studies of incretin as the management for fatty liver disease.
PMID:37273247 | PMC:PMC10237000 | DOI:10.4239/wjd.v14.i5.549
Add to Google Keep
Estimated reading time: 4 minute(s)
Latest: Psychiatryai.com #RAISR4D
Cool Evidence: Engaging Young People and Students in Real-World Evidence ☀️
Real-Time Evidence Search [Psychiatry]
AI Research [Andisearch.com]
Diabetes and fatty liver: Involvement of incretin and its benefit for fatty liver management
🌐 90 Days
VR Related Evidence Matrix
- Lian-Mei-Yin formula alleviates diet-induced hepatic steatosis by suppressing Yap1/FOXM1 pathway-dependent lipid synthesis
- Intestinal Barrier Dysfunction and Gut Microbiota in Non-Alcoholic Fatty Liver Disease: Assessment, Mechanisms, and Therapeutic Considerations
- Incretin-based investigational therapies for the treatment of MASLD/MASH
- Puerarin protects the fatty liver from ischemia-reperfusion injury by regulating the PI3K/AKT signaling pathway
- The gut-liver axis in fatty liver disease: role played by natural products
- Supplementation of Micro- and Macronutrients-A Role of Nutritional Status in Non-Alcoholic Fatty Liver Disease
- Role of Angiotensin II in Non-Alcoholic Steatosis Development
- MiR-18 regulates lipid metabolism of non-alcoholic fatty liver disease via IGF1
- Exploring the role of genetic variations in NAFLD: implications for disease pathogenesis and precision medicine approaches
- Prevalences of Hypertension, Type 2 Diabetes Mellitus, and Cardiovascular Disease in a Cohort of Puerto Ricans with Non-alcoholic Fatty Liver Disease
- The effects of replacing ghee with rapeseed oil on liver steatosis and enzymes, lipid profile, insulin resistance, and anthropometric measurements in patients with non-alcoholic fatty liver disease: A randomized controlled clinical trial
- Muscle strength and non-alcoholic fatty liver disease/metabolic-associated fatty liver disease
- Iron metabolism and ferroptosis in Non-alcoholic fatty liver disease: what is our next step?
- Prevalence of nonalcoholic fatty liver disease and liver cirrhosis in Chinese adults with type 2 diabetes mellitus
- A Review: Cytochrome P450 in Alcoholic and Non-Alcoholic Fatty Liver Disease
- Association of physical activity and sports participation with insulin resistance and non-alcoholic fatty liver disease in people with type 1 diabetes
- Impact of the diagnosis of metabolic dysfunction-associated fatty liver disease and non-alcoholic fatty liver disease in patients undergoing liver transplantation for hepatocellular carcinoma
- The Regulatory Mechanism of Smilax China L. Saponins against Nonalcoholic Fatty Liver Is Revealed by Metabolomics and Transcriptomics
- Impact of Transgenerational Nutrition on Nonalcoholic Fatty Liver Disease Development: Interplay between Gut Microbiota, Epigenetics and Immunity
- Liver Lipidomics Analysis Revealed the Protective mechanism of Zuogui Jiangtang Qinggan Formula in type 2 diabetes mellitus with non-alcoholic fatty liver disease
- Liver Lipidomics Analysis Revealed the Protective mechanism of Zuogui Jiangtang Qinggan Formula in type 2 diabetes mellitus with non-alcoholic fatty liver disease
- Serum bile acid and unsaturated fatty acid profiles of non-alcoholic fatty liver disease in type 2 diabetic patients
- EXPRESS: Association of Statins with Onset and Progression of Non-Alcoholic Fatty Liver Disease in Patients with Diabetes
- EXPRESS: Association of Statins with Onset and Progression of Non-Alcoholic Fatty Liver Disease in Patients with Diabetes
- Galectin-3 and Severity of Liver Fibrosis in Metabolic Dysfunction-Associated Fatty Liver Disease
- Role of prostaglandin E2 and its receptors in chronic liver disease
- Hypercaloric low-carbohydrate high-fat diet protects against the development of nonalcoholic fatty liver disease in obese mice in contrast to isocaloric Western diet
- Semaglutide combined with empagliflozin vs. monotherapy for non-alcoholic fatty liver disease in type 2 diabetes: Study protocol for a randomized clinical trial
- Deficiency of ADAR2 ameliorates metabolic-associated fatty liver disease via AMPK signaling pathways in obese mice
- Targeting metabolic-associated fatty liver disease in diabetic kidney disease: A call to action
- Role of the angiopoietin-like protein family in the progression of NAFLD
- Beneficial Effects of Dietary Flaxseed on Non-Alcoholic Fatty Liver Disease
- The Influence of Emodin Succinyl Ethyl Ester on Non-Alcoholic Steatohepatitis Induced by a Diet High in Fructose, Cholesterol, and Fat in Mice
- Interplay between metabolic dysfunction-associated fatty liver disease and renal function: An intriguing pediatric perspective
- SGLT2i impact on HCC incidence in patients with fatty liver disease and diabetes: a nation-wide cohort study in South Korea
- Triglyceride Glucose Index is Associated with Ultrasonographic Fatty Liver Indicator in Children and Adolescents with Non-alcoholic Fatty Liver Disease
- Research progress on the mechanism of action of heme oxygenase-1 regulating ferroptosis in non-alcoholic fatty liver disease
- Correlation of Grades of Non-alcoholic Fatty Liver on Ultrasound With Blood Parameters
- 3D microscaffolds with triple-marker sensitive nanoprobes for studying fatty liver disease in vitro
- Comparison of size of the liver between patients with non-alcoholic fatty liver disease and healthy controls
- Natural compounds proposed for the management of non-alcoholic fatty liver disease
- Features of exocrine pancreatic insufficiency in patients with non-alcoholic fatty liver disease in combination with type 2 diabetes and COVID-19
- Epidemiology, screening, and Co-management of type 2 diabetes mellitus and Metabolic-dysfunction associated steatotic liver disease
- Interactions between the metabolic syndrome and alcohol consumption increases the risk of liver disease
- Bioengineering scalable and drug-responsive in vitro human multicellular non-alcoholic fatty liver disease microtissues encapsulated in the liver extracellular matrix-derived hydrogel
- THE GLOBAL EPIDEMIOLOGY OF NON-ALCOHOLIC FATTY LIVER DISEASE AND NON-ALCOHOLIC STEATOHEPATITIS AMONG PATIENTS WITH TYPE 2 DIABETES
- Research progress in the regulation of pathogenesis and the transformation of chronic liver disease by short-chain fatty acids
- Role of FXR in the development of NAFLD and intervention strategies of small molecules
- Bacteroides and NAFLD: pathophysiology and therapy
- Lactiplantibacillus plantarum ZDY2013 Inhibits the Development of Non-Alcoholic Fatty Liver Disease by Regulating the Intestinal Microbiota and Modulating the PI3K/Akt Pathway
- Advances in management of metabolic dysfunction-associated steatotic liver disease: from mechanisms to therapeutics
- Cardiometabolic and Metabolic Profiles of Lean/Normal, Overweight and Obese Patients with Nonalcoholic Fatty Liver Disease
- Analysis of non-alcoholic fatty liver disease differences from metabolic dysfunction-associated fatty liver disease based on clinical features
- Non-invasive tools for liver steatosis and steatohepatitis predict incidence of diabetes, cardiovascular disease and mortality 20 years later: The ATTICA cohort study (2002-2022)
- Effect of Zuogui Jiangtang Qinggan Formula on lipid metabolism in db/db mouse model of type 2 diabetes mellitus complicated with non-alcoholic fatty liver disease
- Emerging roles of RNA-binding proteins in fatty liver disease
- Investigating the Role of Non-Coding RNA in Non-Alcoholic Fatty Liver Disease
- Changes in the terminology and diagnostic criteria of non-alcoholic fatty liver disease: Implications and opportunities
- Fecal microbiota transplantation for treatment of non-alcoholic fatty liver disease: Mechanism, clinical evidence, and prospect
- Nonalcoholic Fatty Liver Disease and Ethnicity: Lessons Learned from the Arab Population in Israel
- Spleen volume is independently associated with non-alcoholic fatty liver disease, liver volume and liver fibrosis
- Semaglutide alters gut microbiota and improves NAFLD in db/db mice
- MAFLD as part of systemic metabolic dysregulation
- MAFLD as part of systemic metabolic dysregulation
Evidence Blueprint
Diabetes and fatty liver: Involvement of incretin and its benefit for fatty liver management
☊ AI-Driven Related Evidence Nodes
(recent articles with at least 5 words in title)
More Evidence
Diabetes and fatty liver: Involvement of incretin and its benefit for fatty liver management
🌐 365 Days
VR Related Evidence Matrix
- SGLT-2 Inhibitors for Non-Alcoholic Fatty Liver Disease: A Review
- Fatty liver disease's renaming impacts on drug clinical trials
- Effect of the nomenclature of non-alcoholic fatty liver disease on diagnosis and treatment of fatty liver disease concomitant with other liver diseases
- Non-alcoholic fatty liver disease: pathophysiological concepts and treatment options
- Lian-Mei-Yin formula alleviates diet-induced hepatic steatosis by suppressing Yap1/FOXM1 pathway-dependent lipid synthesis
- Diabetes Mellitus among Patients with Non-alcoholic Fatty Liver Disease Visiting the Outpatient Department of Internal Medicine in a Tertiary Care Centre
- Risk factors for macro vascular disease in type 2 diabetes mellitus patients with non-alcoholic fatty liver disease
- Intestinal Barrier Dysfunction and Gut Microbiota in Non-Alcoholic Fatty Liver Disease: Assessment, Mechanisms, and Therapeutic Considerations
- Comparison of aspartate aminotransferase platelet ratio index score and insulin resistance in type 2 diabetes mellitus with non-alcoholic fatty liver disease
- Sirt6 ablation in the liver causes fatty liver that increases cancer risky by upregulating Serpina12
- Sirt6 ablation in the liver causes fatty liver that increases cancer risky by upregulating Serpina12
- Incretin-based investigational therapies for the treatment of MASLD/MASH
- Why do some glucose-lowering agents improve non-alcoholic fatty liver disease whereas others do not? A narrative review in search of a unifying hypothesis
- The future of incretins in the treatment of obesity and non-alcoholic fatty liver disease
- Impact of Porphyromonas gingivalis-odontogenic infection on the pathogenesis of non-alcoholic fatty liver disease
- Research progress of celastrol on the prevention and treatment of metabolic associated fatty liver disease
- Divergent pathways of liver fat accumulation, oxidation, and secretion in lipodystrophy versus obesity-associated NAFLD
- What are the common downstream molecular events between alcoholic and nonalcoholic fatty liver?
- What are the common downstream molecular events between alcoholic and nonalcoholic fatty liver?
- Puerarin protects the fatty liver from ischemia-reperfusion injury by regulating the PI3K/AKT signaling pathway
- Insulin resistance and adipose tissue interactions as the cornerstone of metabolic (dysfunction)-associated fatty liver disease pathogenesis
- Metabolic dysfunction-associated fatty liver disease in people living with HIV
- Mitochondrial metabolic dysfunction and non-alcoholic fatty liver disease: new insights from pathogenic mechanisms to clinically targeted therapy
- Insulin Resistance, Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: Clinical and Experimental Perspective
- Liver Fat Storage Is a Better Predictor of Coronary Artery Disease than Visceral Fat
- Non-Alcoholic Fatty Liver Disease and Liver Fibrosis in Persons with Type 2 Diabetes Mellitus in Ghana: A Study of Prevalence, Severity, and Contributing Factors Using Transient Elastography
- The gut-liver axis in fatty liver disease: role played by natural products
- Dysregulation of Lipid and Glucose Metabolism in Nonalcoholic Fatty Liver Disease
- Supplementation of Micro- and Macronutrients-A Role of Nutritional Status in Non-Alcoholic Fatty Liver Disease
- Autophagy and the unfolded protein response shape the non-alcoholic fatty liver landscape: decoding the labyrinth
- Enhanced non-alcoholic fatty liver detection: Computed tomography scan image analysis and noise reduction with morphological dilation
- Non-alcoholic fatty liver disease, metabolic syndrome, and type 2 diabetes mellitus: where do we stand today?
- Non-Alcoholic Fatty Liver Disease and Diabetes: the bad marriage
- Non-alcoholic fatty liver disease and periodontal disease: A systematic review and meta-analysis of cross-sectional studies
- Ufmylation on UFBP1 alleviates non-alcoholic fatty liver disease by modulating hepatic endoplasmic reticulum stress
- Type 2 Diabetes Mellitus and Liver Disease: Across the Gut-Liver Axis from Fibrosis to Cancer
- IL-6 trans-signaling is increased in diabetes, impacted by glucolipotoxicity and associated with liver stiffness and fibrosis in fatty liver disease
- Therapeutic outcome of dapagliflozin in patients with type 2 diabetes and non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials
- Type 2 Diabetes Mellitus, Non-Alcoholic Fatty Liver Disease, and Metabolic Repercussions: The Vicious Cycle and Its Interplay with Inflammation
- Role of Angiotensin II in Non-Alcoholic Steatosis Development
- Metabolic dysfunction: The silenced connection with fatty liver disease
- MiR-18 regulates lipid metabolism of non-alcoholic fatty liver disease via IGF1
- Association of thyroid function with non-alcoholic fatty liver disease in recent-onset diabetes
- Macrophage heterogeneity role in NAFLD and NASH disease progression
- The significance of omega-3 fatty acids in the treatment of non-alcoholic fatty liver disease
- Liver steatosis as a predictor of incident diabetes in adults: a prospective evaluation in the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil)
- Genetic variants in HFE are associated with non-alcoholic fatty liver disease in lean individuals
- Corrected and republished from: Metabolic associated liver disease
- High prevalence of de novo metabolic dysfunction-associated fatty liver disease after liver transplantation and the role of controlled attenuation parameter
- Exploring the role of genetic variations in NAFLD: implications for disease pathogenesis and precision medicine approaches
- Non-alcoholic fatty liver disease is associated with hyperandrogenism in women with polycystic ovary syndrome
- Prevalences of Hypertension, Type 2 Diabetes Mellitus, and Cardiovascular Disease in a Cohort of Puerto Ricans with Non-alcoholic Fatty Liver Disease
- TIME-RESTRICTED FEEDING COMBINED WITH RESISTANCE EXERCISE TRAINING PREVENTS OBESITY AND IMPROVES LIPID METABOLISM IN THE LIVER OF MICE FED A HIGH-FAT DIET
- Insulin pump therapy in type 1 diabetes is associated with lower indices of Non-Alcoholic Fatty Liver in non-obese women but not men
- The effects of replacing ghee with rapeseed oil on liver steatosis and enzymes, lipid profile, insulin resistance, and anthropometric measurements in patients with non-alcoholic fatty liver disease: A randomized controlled clinical trial
- Effects of sodium-glucose co-transporter 2 inhibitors on liver fibrosis in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: An updated meta-analysis of randomized controlled trials
- Adipose-derived extracellular vesicles - a novel cross-talk mechanism in insulin resistance, non-alcoholic fatty liver disease, and polycystic ovary syndrome
- Muscle strength and non-alcoholic fatty liver disease/metabolic-associated fatty liver disease
- Iron metabolism and ferroptosis in Non-alcoholic fatty liver disease: what is our next step?
- An update on the effect of sodium glucose cotransporter 2 inhibitors on non-alcoholic fatty liver disease: A systematic review of clinical trials
- A high-fat diet supplemented with medium-chain triglycerides ameliorates hepatic steatosis by reducing ceramide and diacylglycerol accumulation in mice
- Prevalence of nonalcoholic fatty liver disease and liver cirrhosis in Chinese adults with type 2 diabetes mellitus
- Comparison of all-cause mortality associated with non-alcoholic fatty liver disease and metabolic dysfunction-associated fatty liver disease
- A Review: Cytochrome P450 in Alcoholic and Non-Alcoholic Fatty Liver Disease